Please assess the completion status of the following clinical trial:

Trial Title: Role of Plavix in Hemorrhagic and Ischemic Complications of Catheterization.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient less than 18 years of age~2. Patient referred as an outpatient for elective cardiac catheterization with coronary angiography and ad hoc percutaneous coronary intervention (if coronary anatomy suitable)~3. Patient has stable angina or a stress test suggestive of ischemia and/or prior myocardial infarction~4. Anticipated femoral arterial approach for the cardiac catheterization procedure~5. Patient provides written informed consent~Exclusion Criteria:~Patients will be excluded if any of the following are present:~1. Use of clopidogrel or ticlopidine during the 14 days prior to the scheduled procedure~2. Known hypersensitivity to clopidogrel (regardless of desensitization) or to any other components of Plavix~3. Contraindication to clopidogrel, including~   1. Pre-existing bleeding disorder or hematological dyscrasia~  2. INR \>1.4 immediately prior to the scheduled procedure~  3. Platelet count \<50 K/uL~  4. Significant bleeding during the 14 days prior to the scheduled procedure~  5. Surgery or invasive procedure at a non-compressible location during the 30 days prior to the scheduled procedure~  6. Anticipated need for surgery or other invasive procedure within 30 days following the scheduled procedure~  7. Patient states unwillingness to undergo transfusion of red blood cells even in the event of life threatening bleeding~4. Unstable cardiac status~   1. Patient was admitted for a cardiac condition and referred as an inpatient for cardiac catheterization~  2. Myocardial infarction diagnosed as occurring during the 30 days prior to the scheduled procedure~  3. Pre-procedure troponin-T \>0.01 ng/mL~  4. Unstable angina~   i. Ischemic symptoms at rest ii. Ischemic symptoms with mild exertion (e.g., walking one to two level blocks or climbing one flight of stairs) e. Pre-procedure electrocardiogram with ST segment changes indicative of ongoing myocardial injury or ischemia~5. Chronic renal failure (which may raise troponin-T levels)~   1. Patient currently undergoing dialysis~  2. Serum creatinine \>2 mg/dL~  3. Estimated glomerular filtratation rate (eGFR using the MDRD formula) \<45 mL/min/1.73 m2~6. Procedural factors~   1. Patient does not require coronary angiography as part of the scheduled cardiac catheterization~  2. Patient is not a candidate for percutaneous coronary intervention during the same procedure as the diagnostic coronary angiography~  3. Anticipated need for arterial access using brachial, radial or other non-femoral approach~  4. Anticipated need to access the femoral artery via a femoral bypass graft~  5. Anticipated need for an arterial sheath 6 French in size or larger (e.g., planned evaluation of aortic stenosis or hypertrophic cardiomyopathy)~  6. Anticipated need for heparin anticoagulation during the diagnostic cardiac catheterization procedure (e.g., crossing a stenosed aortic valve with a 0.035 wire, planned intra-vascular ultrasound or pressure wire study)~7. Woman of child-bearing potential who does not have a negative pregnancy test immediately prior to the scheduled procedure~8. Participation in another non-observational clinical study that has not yet completed all mandatory follow-up (i.e., patients who are participating in a natural history observational registry where no active therapy is being investigated may participate)~9. Prior participation in this study~10. Inability to provide written informed consent or demonstrate understanding of the risks and benefits associated with participation in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Clopidogrel 600 mg pre-treatment (Type: ACTIVE_COMPARATOR): Patients will receive 600 mg Clopidogrel load \>2 hours pre-angiography with possibility for ad hoc PCI based on angiographic results
- No clopidogrel 600 mg pretreatment (Type: ACTIVE_COMPARATOR): Patients will receive 600 mg Clopidogrel load after PCI, if performed
- 5Fr arterial access sheath (Type: ACTIVE_COMPARATOR): Patients will have angiography performed using 5Fr sheath. If PCI required, sheath will be upsized.
- 6Fr arterial access sheath (Type: ACTIVE_COMPARATOR): Patients will have angiography performed using 6Fr sheath

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues